Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Divalproex (250mg) Prolonged Release
Therapeutic Category
Antiepileptic, Neurology, Sedative or Antianxiety
Dosage Form
Tablet
Packaging Type
Alu Strip
Packaging
10x10
Price
₹120/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Divalxyle ER 250 Tablet contains Divalproex Sodium in a prolonged-release formulation, offering a sustained and controlled release of the active ingredient for effective management of neurological and psychiatric conditions. Divalproex is an anticonvulsant and mood stabilizer that works by restoring the balance of neurotransmitters in the brain, making it a preferred choice for various conditions requiring long-term management.
Divalproex is widely used in the treatment of epilepsy, specifically for partial seizures, generalized tonic-clonic seizures, and absence seizures. It is also effective in managing bipolar disorder, reducing the frequency and intensity of manic episodes. Additionally, it is prescribed for the prophylaxis of migraine headaches, helping patients experience fewer and less severe episodes.
This formulation ensures prolonged therapeutic effects, reducing the frequency of dosing and enhancing patient compliance. The controlled-release nature of the tablet minimizes fluctuations in blood levels, offering steady symptom management and reducing the risk of side effects.
Common side effects may include nausea, dizziness, fatigue, and mild tremors. Rarely, it may cause liver dysfunction or weight gain.
Divalxyle ER 250 Tablet is indicated for the treatment of epilepsy, bipolar disorder, and the prevention of migraines.
Use this medication strictly under the guidance of a healthcare provider. Regular monitoring of liver function and blood parameters is recommended.
Store in a cool, dry place below 30°C, away from direct sunlight and moisture. Keep out of reach of children.
Composition : Divalproex (500mg) Prolonged Release Tablet
Composition : Brivaracetam I.P. 100mg Tablet
Composition : Brivaracetam I.P. 50mg Tablet
Composition : Brivaracetam (10mg) Injection
Composition : Duloxetine (20mg)
Composition : Duloxetine (30mg) Tablet
Composition : Duloxetine (40mg) Tablet
Composition : Duloxetine (60mg) Tablet
Composition : Duloxetine (20mg) + Methylcobalamin (500mcg)
Composition : Duloxetine 20mg + Methylcobalamin 750mcg
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Divalproex 250mg PR (Prolonged Release) Tablet has strong demand in the neurology and psychiatry segment, making it a valuable prescription-based product for medical distributors, wholesalers, and pharma franchise partners in the PCD pharma pharma franchise market.
Medical distributors and wholesalers can benefit from consistent demand in epilepsy, seizure disorders, bipolar disorder, and migraine prophylaxis. The prolonged-release form supports stable drug levels and better patient compliance in long-term therapy.
Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities for Divalproex 250mg Prolonged Release Tablet with monopoly rights, quality packaging, competitive pricing, and reliable supply support for distributors and medical agencies.
Wholesalers and medical agencies benefit from steady chronic prescription demand, repeat sales, and strong acceptance in neurology and psychiatry practice when partnering with Cafoli Lifecare.
Medical distributors, stockists, wholesalers, and pharma professionals interested in this neurological formulation can contact Cafoli Lifecare to discuss PCD pharma franchise opportunities, pricing, and distribution support services.